Valneva affirms clinical trial of inactivated COVID-19 vaccine- VLA2001

While the world is still awaiting a positive response on COVID-19 vaccines owing to the ruckus created by the pandemic, vaccine company Valneva has been focusing on prevention against various diseases and has recently announced entering into an initial Phase 1/2 clinical study for its adjuvanted, inactivated COVID-19 vaccine candidate- VLA2001.

It has been claimed that the novel vaccine candidate- VLA2001- makes use of the production platform of the company’s patented Japanese encephalitis vaccine, IXIARO and is potentially the first officially publicized inactivated vaccine against COVID-19 to begin clinical development across the states of Europe.

For the record, VLA2001-201 study is a randomized, double blind trial analyzing the safety and immunogenicity of three dose levels in about 150 healthy adults. Moreover, the study is expected to be conducted in study sites across the UK in support with the National Institute for Health Research.

Taking the monumental steps in launching the first COVID-19 vaccine, UK Secretary of State for Business, Energy and Industrial Strategy of Valneva- Alok Sharma cited that the company is delighted to announce the commencement of life-saving clinical trials to test the safety and effectiveness of its vaccine, which is being developed in the facility of UK.

While on the other hand, Thomas Lingelbach, CEO of Valneva, quoted that the teams have been relentlessly working towards the development of its differentiated vaccine candidate and is obliged to the support and dedication offered by the teams and the UK government.

He stated that the company has already announced its plans of ramping up the manufacturing capacities and commencing manufacturing at full-scale so that they can produce the vaccine and make it widely accessible across the globe.

Speculations have it that Valneva, in mid-2020, announced a major COVID-19 vaccine partnership with the government of United Kingdom. Under this pact, if the development of vaccine is successful, the company would offer UK govt. with over 60 million vaccine doses in the second half of 2021 and the government would have options of granting further 130 million doses from 2022 to 2025.

Source Credit: